Bristol-Myers Squibb Co (XSWX:BMY) Total Long-Term Assets: CHF46,662 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BMY Bristol-Myers Squibb Co XSWX:BMY
78 GF Score
Price CHF50.31
GF Value CHF45.07
! 7 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Total Long-Term Assets?

Bristol-Myers Squibb Co XSWX:BMY +1.42% 78 Total Long-Term Assets is CHF46,662 Mil as of Mar. 2026. GuruFocus rates XSWX:BMY with a GF Score™ of 78/100 and a GF Value™ of CHF45.07. The stock has 7 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Bristol-Myers Squibb Co's Total Long-Term Assets for the quarter that ended in Mar. 2026 was CHF46,662 Mil.

Bristol-Myers Squibb Co Total Long-Term Assets Related Terms

Bristol-Myers Squibb Co Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Total Long-Term Assets Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70,043.89 64,789.99 54,818.81 56,012.99 48,330.39

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54,468.64 49,974.39 48,768.29 48,330.39 46,661.70
XSWX:BMY
78GF Score
Bristol-Myers Squibb Co XSWX:BMY
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of CHF46,662 Mil mean?
Bristol-Myers Squibb Co (XSWX:BMY) has a Total Long-Term Assets of CHF46,662 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Total Long-Term Assets too high?
Bristol-Myers Squibb Co's current Total Long-Term Assets is CHF46,662 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Total Long-Term Assets compare to PFE and GILD?
Bristol-Myers Squibb Co's Total Long-Term Assets of CHF46,662 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Total Long-Term Assets is CHF46,662 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Bristol-Myers Squibb Co (XSWX:BMY) has a current Total Long-Term Assets of CHF46,662 Mil. The stock's GF Value™ is CHF45.07, compared to a current price of CHF50.31 — trading 11.6% above its estimated fair value. The current Total Long-Term Assets is CHF46,662 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current Total Long-Term Assets is CHF46,662 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of CHF50.31 is trading 11.6% above its estimated GF Value™ of CHF45.07.

Key valuation signals for XSWX:BMY:

  • Total Long-Term Assets: CHF46,662 Mil
  • GF Value™: CHF45.07 vs. price of CHF50.31 (11.6% above fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
78GF Score

Get the complete analysis for XSWX:BMY

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF50.31
Price
CHF45.07
GF Value